News | Magnetic Resonance Imaging (MRI) | December 29, 2015

Novel MRI Imaging Agent More Effectively Monitors Impact of Treatment in Lung, Prostate Cancers

Novel MRI Imaging Agent More Effectively Monitors Impact of Treatment in Lung, Prostate Cancers

Molecular imaging of the GRPR biomarker on mice xenografted with PC3 and H441 cells by T1-weighted spin echo MR imaging and NIR imaging.

December 29, 2015 — A method to better trace changes in cancers and treatment of the prostate and lung without the limitations associated with radiation has been developed with a new magnetic resonance imaging (MRI) imaging agent (Scientific Reports. doi:10.1038/srep16214).

The researchers developed a new imaging agent they named ProCA1.GRPR, and demonstrated that it leads to strong tumor penetration and is capable of targeting the gastrin-releasing peptide receptor expressed on the surface of diseased cells, including prostate, cervical and lung cancer cells.

Molecular imaging of cancer predictors using MRI offers better and improved understanding of various cancers and drug activity during preclinical and clinical treatments. However, one of the major barriers in using MRI in evaluating specific disease predictors for diagnosis and monitoring drug effects is the lack of highly sensitive and specific imaging agents capable of showing the difference between normal tissue and tumors.

"ProCA1.GRPR has a strong clinical translation for human application and represents a major step forward in the quantitative imaging of disease biomarkers without the use of radiation," said lead author Jenny J. Yang, Ph.D., professor and associate director of the Center for Diagnostics and Therapeutics at Georgia State University in Atlanta. "This information is valuable for staging disease progression and monitoring treatment effects."

The researchers' results are an important advancement for molecular imaging. This agent has a unique ability to quantitatively detect expression level and spatial distribution of disease predictors without using radiation.

"Our discovery is of great interest to both chemists and clinicians for disease diagnosis, including noninvasive early detection of human diseases, cancer biology, molecular basis of human diseases, and translational research with preclinical and clinical applications," said coauthor Shenghui Xue, Ph.D., postdoctoral researcher in Georgia State Department of Chemistry.

Improved imaging agents such as ProCA1.GRPR have implications in understanding disease development and treatment.

For more information: www.nature.com/articles/srep16214

Related Content

International Working Group Releases New Multiple Myeloma Imaging Guidelines

X-ray images such as the one on the left fail to indicate many cases of advanced bone destruction caused by multiple myeloma, says the author of new guidelines on imaging for patients with myeloma and related disorders. Image courtesy of Roswell Park Comprehensive Cancer Center.

News | Computed Tomography (CT) | June 17, 2019
An International Myeloma Working Group (IMWG) has developed the first set of new recommendations in 10 years for...
SyMRI Software Receives FDA Clearance for Use With Siemens MRI Systems
Technology | Magnetic Resonance Imaging (MRI) | June 14, 2019
SyntheticMR announced U.S. Food and Drug Administration (FDA) clearance for clinical use of its SyMRI Image and SyMRI...
A high-fidelity 3-D tractography of the left ventricle heart muscle fibers of a mouse

Figure 1. A high-fidelity 3-D tractography of the left ventricle heart muscle fibers of a mouse from Amsterdam Ph.D. researcher Gustav Strijkers.

News | Magnetic Resonance Imaging (MRI) | June 07, 2019
The Amsterdam University Medical Center has won MR Solutions’ Image of the Year 2019 award for the best molecular...
Study Identifies MRI-Guided Radiation Therapy as Growing Market Segment
News | Image Guided Radiation Therapy (IGRT) | June 06, 2019
Revenues from the magnetic resonance imaging (MRI)-guided radiation therapy systems market exceeded $220 million in...
Ann Arbor Startup Launches Augmented Reality MRI Simulator
Technology | Virtual and Augmented Reality | June 04, 2019
SpellBound, an Ann Arbor startup specializing in augmented reality (AR) tools for children in hospitals, has officially...

Photo courtesy of Philips Healthcare

Feature | Radiology Business | May 31, 2019 | By Arjen Radder
Change is a consistent theme in our world today, no matter where you look.
MRI Metal Artifact Reduction Poses Minimal Thermal Risk to Hip Arthroplasty Implants
News | Magnetic Resonance Imaging (MRI) | May 23, 2019
Clinical metal artifact reduction sequence (MARS) magnetic resonance imaging (MRI) protocols at 3 Tesla (3T) on hip...
Henry Ford Hospital's ViewRay MRIdian linear accelerator system allows real-time MRI-guided radiotherapy. Shown is the support staff for this system. In the center of the photo is Benjamin Movsas, M.D., chair of radiation oncology at Henry Ford Cancer Institute. Second from the right is Carrie Glide-Hurst, Ph.D., director of translational research, radiation oncology.

Henry Ford Hospital's ViewRay MRIdian linear accelerator system allows real-time MRI-guided radiotherapy. Shown is the support staff for this system. In the center of the photo is Benjamin Movsas, M.D., chair of radiation oncology at Henry Ford Cancer Institute. Second from the right is Carri Glide-Hurst, Ph.D., director of translational research, radiation oncology.

Feature | Henry Ford Hospital | May 21, 2019 | Dave Fornell, Editor
Henry Ford Hospital thought leaders regularly speak at the radiation oncology and radiology conferences about new res
Videos | Radiation Therapy | May 21, 2019
This is a walk through of the ViewRay MRIdian MRI-guided radiotherapy system installed at ...